JNJ’s Earnings Beat Reveals a Sector Split: MedTech Strength Offsets Pharma Weakness in Healthcare ETFs

Healthcare ETFs tied to Johnson & Johnson may see divergent performance this year—not because of broad sector momentum, but because the company’s MedTech strength is shielding it from its own pharmaceutical setbacks. JNJ reported $24.1 billion in Q1 revenue, beating $23.6 billion in expectations, and earnings per share of $2.70 versus a $2.66 forecast. The beat wasn’t uniform: while Stelara, its once-dominant psoriasis drug, faced declining sales due to competition, the Innovation Medicine segment grew operational sales by 7.4%, fueled by demand for Darzalex and Tremfya. That strength was amplified by the MedTech division, which posted a 4.6% global increase in operational sales, driven by a rebound in elective surgeries and recent cardiovascular device acquisitions. This dual-engine model—long-cycle drug development paired with high-margin surgical and orthopedic tools—is now JNJ’s stabilizing force. The stock has risen nearly 16% in 2026, even as the healthcare sector lags the S&P 500. For ETF investors, the implications are structural. Funds like IHE offer concentrated exposure to pharmaceuticals and will reflect JNJ’s innovation upside—but also its pharma volatility. Broader, more diversified ETFs like XLV, FHLC, and IYH include JNJ as a major holding while spreading risk across medical devices, biotech, and large-cap healthcare names. Global funds like PBPH add international pharma and biotech revenue streams. The divergence within JNJ itself—MedTech gains offsetting legacy drug declines—reveals a deeper split in the sector. Investors now face a choice not just between ETFs, but between models: high-conviction pharma bets or diversified resilience. In 2026, the latter is proving more durable.